Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)Paolo A. Ascierto, Michele Maio, Caroline Robert et al.|Annals of Oncology|2016Cited by 23